Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869571 | 1.00 | MGLL (0.38) | MGLLKIF11ERN1 | |
| SCHEMBL28736451 | 0.82 | MGLL (0.39) | MGLLKIF11 | |
| SCHEMBL29636128 | 0.82 | MGLL (0.39) | MGLLKIF11 | |
| SCHEMBL1277215 | 0.80 | ERN1 (0.38) | MGLLERN1 | |
| SCHEMBL16654613 | 0.76 | MGLL (0.38) | MGLLKIF11 | |
| SCHEMBL29953916 | 0.74 | ENPP2 (0.33) | MGLL | |
| SCHEMBL28047962 | 0.74 | ERN1 (0.43) | KIF11ERN1 | |
| SCHEMBL16193054 | 0.74 | MGLL (0.43) | MGLL | |
| SCHEMBL1231962 | 0.73 | KIF11 (0.48) | MGLLKIF11 | |
| SCHEMBL29525231 | 0.73 | MGLL (0.48) | MGLLKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-11-26 | — | — | US | disclosed |
| EP-3645536-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019002606-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | SELVITA S.A. (PL) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | MGLL 4845/4885KIF11 2886/4885ERN1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.